CNTX

Business Context and Reporting Period

Company: Context Therapeutics Inc. (CNTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Context is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. The company has no commercial products and has not generated any revenue to date. Its pipeline consists of three primary candidates: CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3).

Key Financial Metrics

Note: The company does not report profit margins or debt obligations as it has no revenue and no long-term debt.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 35% (approximately $9.4 million) compared to 2024, driven primarily by higher R&D spending.
• R&D Expense Growth: R&D expenses rose by 40% ($9.2 million). Key drivers included:
  • CT-202: Expenses increased by $4.4 million, largely due to a $2.0 million milestone payment to BioAtla and increased contract manufacturing costs.
  • CTIM-76: Expenses increased by $1.3 million due to clinical trial progression.
  • Personnel Costs: Increased by $3.3 million due to higher headcount and termination benefits.
• Cash Position: Cash and cash equivalents decreased by approximately $28.4 million during the year, reflecting the burn rate from operations and investing activities (including the BioAtla milestone payment).
• Financing Activity: Unlike 2024, which saw significant capital raises ($109.3 million provided by financing), 2025 saw minimal financing activity, with only $15,000 used for offering costs.

Guidance, Outlook, and Risks

Outlook and Milestones

• Liquidity: Management expects current cash reserves ($66.0 million) to fund operations into mid-2027, covering Phase 1a trials for CTIM-76 and CT-95, and the initiation of CT-202 trials.
• CTIM-76: First patient dosed in January 2025. Phase 1a interim data expected in June 2026.
• CT-95: First patient dosed in April 2025. Phase 1a interim data expected in September 2026.
• CT-202: First-in-human trial application submitted in March 2026. First patient dosing expected in Q3 2026.

Material Risks and Contingencies

• Capital Requirements: The company has never been profitable and will require substantial additional funding to continue operations. Failure to raise capital could force delays or termination of programs.
• Intellectual Property: Potential third-party patent claims exist regarding CTIM-76 (patents expiring 2034 and 2042). While the company believes it has defenses, licensing may be required.
• Regulatory and Clinical Risk: All candidates are in early-stage development. Clinical trials may fail to demonstrate safety or efficacy, and regulatory approval is uncertain.
• Legal Proceedings: A stockholder class action regarding the Certificate of Incorporation was filed in February 2026 but was dismissed with prejudice in March 2026 following a stipulated judgment.
• Market Risk: The company previously received a Nasdaq non-compliance notice regarding the minimum bid price rule in February 2025 but has since regained compliance.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "mid-2027" liquidity estimate given the high burn rate and potential for accelerated clinical spending.
• IP Litigation Status: Monitor developments regarding the third-party patents potentially covering CTIM-76 and any resulting licensing negotiations.
• Clinical Data Readouts: Track the release of Phase 1a interim data for CTIM-76 (June 2026) and CT-95 (September 2026) for safety and efficacy signals.
• Financing Plans: Assess the company's strategy for raising additional capital, as the current ATM facility and cash reserves may be insufficient for long-term development without new equity or debt issuance.
• License Obligations: Review future milestone payment obligations under the BioAtla ($122.5 million potential) and Integral Molecular agreements.